Work

Archer: Dacomitinib (D; PF-00299804) Versus Erlotinib (E) for Advanced (ADV) NSCLC; A Randomized Double-Blind Phase III Study

Year: 2012

Type: article

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)31977-3

Authors: M. Boyer, P.A Jänne, T. Mok, K. O'Byrne, L. Paz-Ares, S.S. Ramalingam, J. Liang, I. Taylor, A. Campbell, J. O'Connell, S. Letrent, S.-Y. Lee, V. Antic

Institutions: Dana-Farber Cancer Institute, Chinese University of Hong Kong, St. James's Hospital, Hospital Universitario Virgen del Rocío, Winship Cancer Institute, Pfizer (United States), Pfizer (South Korea), Pfizer (Switzerland)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3000207526

FWCI:

Cites:

Cited by:

Related to: 10